TNO and FAST join forces to accelerate accessible and affordable therapies


TNO and FAST (Financiering en Acceleratie voor Therapieontwikkeling) have launched a strategic collaboration to accelerate the development of advanced therapies, including ATMPs, radiopharmaceuticals, treatments for rare diseases, infectious diseases, and drug repurposing.

Highlights:

  • Shared ambition to accelerate drug discovery by leveraging TNO’s innovation capabilities and deep collaborations with industry, government, and society.

  • Conny Helder (former Minister of Health) appointed as FAST’s new board chair, bringing strong leadership and signalling a strengthened link with TNO in publicly funded therapy programmes.

This partnership combines TNO’s technical and operational strength with FAST’s independent expert role, aiming to scale innovations that are both effective and affordable for patients.

Read more here


  • SpectaCell raises €6 million to accelerate drug development

    For the Leiden Bio Science Park, it is great to see SpectaCell connecting its technology with the biotech ecosystem here in Leiden. SpectaCell will combine its technology development and cell analysis in Ghent with further validation and application within the…

  • LUMC opens dedicated CAR-T department

    Leiden University Medical Center (LUMC) has opened a dedicated department for CAR-T cell therapy, bringing care, research and expertise in this rapidly developing field together in one place. The new department, officially opened on 24 September, marks another step in…